Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc. |
| October 11, 2019 | October 2019 Bond Updates |
|
OSAKA, Japan, Oct. 11, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (Head Office: Osaka; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. (Head Office: Media, PA, USA; President and... |
| View more at: https://www.prnewswire.com:443/news-releases/shionogi-enters-into-a-new-license-agreement-and-research-collaboration-for-the-treatment-of-mycobacterial-diseases-with-hsiri-therapeutics-inc-300936640.html |
| Related News |
|